Salmonella as live trojan horse for vaccine development and cancer gene therapy

Current Gene Therapy

Volumn 10, Issue 1, 2010, Pages 56-76

  Moreno, Maria ^a   Kramer, M Gabriela ^a   Yim, Lucía ^a   Chabalgoity, José A ^a  

^a Universidad de la Republica Instituto de Higiene   (Uruguay)

Author keywords

Cancer; Gene therapy; Infectious diseases; Pathogenicity; Salmonella; Vaccine; Vector

Indexed keywords

ALZHEIMER DISEASE VACCINE; BACTERIAL VACCINE; BACTERIAL VECTOR; CANCER VACCINE; SALMONELLOSIS VACCINE;

ALZHEIMER DISEASE; ANTISENSE THERAPY; CANCER GENE THERAPY; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENICITY; PLASMID; PROTEIN EXPRESSION; REVIEW; SALMONELLA; SALMONELLA TYPHIMURIUM; SALMONELLOSIS;

ANIMALIA; EQUIDAE; SALMONELLA;

EID: 77950786785     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310790945566     Document Type: Review

References (214)

1. Reeves MW, Evins GM, Heiba AA, Plikaytis BD, Farmer JJ, 3rd. Clonal nature of Salmonella typhi and its genetic relatedness to other salmonellae as shown by multilocus enzyme electrophoresis, and proposal of Salmonella bongori comb. J Clin Microbiol 1989; 27(2): 313-320
2. Popoff MY, Bockemuhl J, Gheesling LL. Supplement 2002 (no.46) to the Kauffmann-White scheme. Res Microbiol 2004; 155(7): 568-570
3. Uzzau S, Brown DJ, Wallis T, et al. Host adapted serotypes of Salmonella enterica. Epidemiol Infect 2000; 125(2): 229-255
4. Pardon P, Sanchis R, Marly J, Lantier F, Pepin M, Popoff M. Ovine salmonellosis caused by Salmonella abortus ovis. Ann Rech Vet 1988; 19(4): 221-235
5. Rice DH, Besser TE, Hancock DD. Epidemiology and virulence assessment of Salmonella dublin. Vet Microbiol 1997; 56(1-2):111-124
6. Encheva V, Wait R, Begum S, Gharbia SE, Shah HN. Protein expression diversity amongst serovars of Salmonella enterica. Microbiology 2007; 153(Pt 12): 4183-4193
7. Soyer Y, Orsi RH, Rodriguez-Rivera LD, Sun Q, Wiedmann M. Genome wide evolutionary analyses reveal serotype specific patterns of positive selection in selected Salmonella serotypes. BMC Evol Biol 2009; 9: 264.
8. Holt KE, Thomson NR, Wain J, et al. Pseudogene accumulation in the evolutionary histories of Salmonella enterica serovars Paratyphi A and Typhi. BMC Genomics 2009; 10: 36.
9. Thomson NR, Clayton DJ, Windhorst D, et al. Comparative genome analysis of Salmonella Enteritidis PT4 and Salmonella Gallinarum 287/91 provides insights into evolutionary and host adaptation pathways. Genome Res 2008; 18(10): 1624-1637
10. Porwollik S, Boyd EF, Choy C, et al. Characterization of Salmonella enterica subspecies I genovars by use of microarrays. J Bacteriol 2004; 186(17): 5883-5898
11. [II] Porwollik S, Santiviago CA, Cheng P, Florea L, Jackson S, McClelland M. Differences in gene content between Salmonella enterica serovar Enteritidis isolates and comparison to closely related serovars Gallinarum and Dublin. J Bacteriol 2005; 187(18):6545-6555
12. Pullinger GD, Dziva F, Charleston B, Wallis TS, Stevens MP. Identification of Salmonella enterica serovar Dublin-specific sequences by subtractive hybridization and analysis of their role in intestinal colonization and systemic translocation in cattle. Infect Immun 2008; 76(11): 5310-5321
13. Ansong C, Yoon H, Norbeck AD, et al. Proteomics analysis of the causative agent of typhoid fever. J Proteome Res 2008; 7(2): 546-557
14. Parkhill J, Dougan G, James KD, et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001; 413(6858): 848-852
15. McClelland M, Sanderson KE, Clifton SW, et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet 2004; 36(12): 1268-1274
16. Langridge GC, Wain J, Nair S. Invasive Salmonellosis in Humans. In: Dougan G, Ed. Escherichia coli and Salmonella: cellular and molecular biology. USA: ASM Press 2008.
17. Raffatellu M, Wilson RP, Winter SE, Baumler AJ. Clinical pathogenesis of typhoid fever. J Infect Dev Ctries 2008; 2(4): 260-266
18. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009; 87(5): 400-412
19. McClelland M, Sanderson KE, Spieth J, et al. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 2001; 413(6858): 852-856
20. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000; 97(12): 6640-6645
21. Husseiny MI, Hensel M. Rapid method for the construction of Salmonella enterica Serovar Typhimurium vaccine carrier strains. Infect Immun 2005; 73(3): 1598-1605
22. Tsolis RM, Kingsley RA, Townsend SM, Ficht TA, Adams LG, Baumler AJ. Of mice, calves, and men. Comparison of the mouse typhoid model with other Salmonella infections. Adv Exp Med Biol 1999; 473: 261-274
23. Hapfelmeier S, Hardt WD. A mouse model for S. typhimuriuminduced enterocolitis. Trends Microbiol 2005; 13(10): 497-503.
24. Groisman EA, Ochman H. How Salmonella became a pathogen. Trends Microbiol 1997; 5(9): 343-349
25. Marcus SL, Brumell JH, Pfeifer CG, Finlay BB. Salmonella pathogenicity islands: big virulence in small packages. Microbes Infect 2000; 2(2): 145-156
26. Porwollik S, McClelland M. Lateral gene transfer in Salmonella. Microbes Infect 2003; 5(11): 977-989
27. Hensel M. Evolution of pathogenicity islands of Salmonella enterica. Int J Med Microbiol 2004; 294(2-3): 95-102.
28. Blondel CJ, Jimenez JC, Contreras I, Santiviago CA. Comparative genomic analysis uncovers 3 novel loci encoding type six secretion systems differentially distributed in Salmonella serotypes. BMC Genomics 2009; 10: 354.
29. Vernikos GS, Parkhill J. Interpolated variable order motifs for identification of horizontally acquired DNA: revisiting the Salmonella pathogenicity islands. Bioinformatics 2006; 22(18): 2196-2203
30. Chiu CH, Tang P, Chu C, et al. The genome sequence of Salmonella enterica serovar Choleraesuis, a highly invasive and resistant zoonotic pathogen. Nucleic Acids Res 2005; 33(5): 1690-1698
31. Shah DH, Lee MJ, Park JH, et al. Identification of Salmonella gallinarum virulence genes in a chicken infection model using PCR-based signature-tagged mutagenesis. Microbiology 2005;151(Pt 12): 3957-3968
32. Andrews-Polymenis HL, Santiviago CA, McClelland M. Novel genetic tools for studying food-borne Salmonella. Curr Opin Biotechnol 2009; 20(2): 149-157
33. Penheiter KL, Mathur N, Giles D, Fahlen T, Jones BD. Non-invasive Salmonella typhimurium mutants are avirulent because of an inability to enter and destroy M cells of ileal Peyer's patches. Mol Microbiol 1997; 24(4): 697-709.
34. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, et al. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect Immun 2003; 71(5): 2839-2858
35. Morgan E, Campbell JD, Rowe SC, et al. Identification of hostspecific colonization factors of Salmonella enterica serovar Typhimurium. Mol Microbiol 2004; 54(4): 994-1010.
36. Carnell SC, Bowen A, Morgan E, Maskell DJ, Wallis TS, Stevens MP. Role in virulence and protective efficacy in pigs of Salmonella enterica serovar Typhimurium secreted components identified by signature-tagged mutagenesis. Microbiology 2007; 153(Pt 6):1940-1952
37. Ochman H, Soncini FC, Solomon F, Groisman EA. Identification of a pathogenicity island required for Salmonella survival in host cells. Proc Natl Acad Sci USA 1996; 93(15): 7800-7804
38. Shea JE, Hensel M, Gleeson C, Holden DW. Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium. Proc Natl Acad Sci USA 1996; 93(6): 2593-2597
39. Hensel M. Salmonella pathogenicity island 2. Mol Microbiol 2000;36(5): 1015-1023
40. Jones BD, Ghori N, Falkow S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J Exp Med 1994; 180(1):15-23.
41. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2(4): 361-367
42. Vazquez-Torres A, Jones-Carson J, Baumler AJ, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 1999; 401(6755): 804-808
43. Galan JE, Curtiss R, 3rd. Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc Natl Acad Sci USA 1989; 86(16): 6383-6387
44. Galan JE. Salmonella interactions with host cells: type III secretion at work. Annu Rev Cell Dev Biol 2001; 17: 53-86.
45. Haque A, Bowe F, Fitzhenry RJ, et al. Early interactions of Salmonella enterica serovar typhimurium with human small intestinal epithelial explants. Gut 2004; 53(10): 1424-1430
46. McGhie EJ, Brawn LC, Hume PJ, Humphreys D, Koronakis V. Salmonella takes control: effector-driven manipulation of the host. Curr Opin Microbiol 2009; 12(1): 117-124
47. Altier C. Genetic and environmental control of salmonella invasion. J Microbiol 2005; 43 Spec No: 85-92.
48. Bumann D. Examination of Salmonella gene expression in an infected mammalian host using the green fluorescent protein and two-colour flow cytometry. Mol Microbiol 2002; 43(5): 1269-1283
49. Winnen B, Schlumberger MC, Sturm A, et al. Hierarchical effector protein transport by the Salmonella Typhimurium SPI-1 type III secretion system. PLoS One 2008; 3(5): e2178.
50. Kubori T, Galan JE. Temporal regulation of salmonella virulence effector function by proteasome-dependent protein degradation. Cell 2003; 115(3): 333-342
51. Fields PI, Swanson RV, Haidaris CG, Heffron F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci USA 1986; 83(14): 5189-5193
52. Dunlap NE, Benjamin WH, Jr., Briles DE. The intracellular nature of Salmonella infection during the early stages of mouse typhoid. Immunol Ser 1994; 60: 303-312
53. Geddes K, Cruz F, Heffron F. Analysis of cells targeted by Salmonella type III secretion in vivo. PLoS Pathog 2007; 3(12): e196.
54. Steele-Mortimer O. The Salmonella-containing vacuole: moving with the times. Curr Opin Microbiol 2008; 11(1): 38-45.
55. Valdivia RH, Falkow S. Fluorescence-based isolation of bacterial genes expressed within host cells. Science 1997; 277(5334): 2007-2011
56. Eriksson S, Lucchini S, Thompson A, Rhen M, Hinton JC. Unravelling the biology of macrophage infection by gene expression profiling of intracellular Salmonella enterica. Mol Microbiol 2003;47(1): 103-118
57. Jantsch J, Cheminay C, Chakravortty D, Lindig T, Hein J, Hensel M. Intracellular activities of Salmonella enterica in murine dendritic cells. Cell Microbiol 2003; 5(12): 933-945
58. Ellermeier JR, Slauch JM. Adaptation to the host environment: regulation of the SPI1 type III secretion system in Salmonella enterica serovar Typhimurium. Curr Opin Microbiol 2007; 10(1): 24-29
59. Fass E, Groisman EA. Control of Salmonella pathogenicity island-2 gene expression. Curr Opin Microbiol 2009; 12(2): 199-204.
60. Brawn LC, Hayward RD, Koronakis V. Salmonella SPI1 effector SipA persists after entry and cooperates with a SPI2 effector to regulate phagosome maturation and intracellular replication. Cell Host Microb 2007; 1(1): 63-75.
61. Lawley TD, Chan K, Thompson LJ, Kim CC, Govoni GR, Monack DM. Genome-wide screen for Salmonella genes required for longterm systemic infection of the mouse. PLoS Pathog 2006; 2(2):e11.
62. Coburn B, Li Y, Owen D, Vallance BA, Finlay BB. Salmonella enterica serovar Typhimurium pathogenicity island 2 is necessary for complete virulence in a mouse model of infectious enterocolitis. Infect Immun 2005; 73(6): 3219-3227
63. Giacomodonato MN, Uzzau S, Bacciu D, et al. SipA, SopA, SopB, SopD and SopE2 effector proteins of Salmonella enterica serovar Typhimurium are synthesized at late stages of infection in mice. Microbiology 2007; 153(Pt 4): 1221-1228
64. Hapfelmeier S, Stecher B, Barthel M, et al. The Salmonella pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. J Immunol 2005; 174(3): 1675-1685
65. Bustamante VH, Martinez LC, Santana FJ, Knodler LA, SteeleMortimer O, Puente JL. HilD-mediated transcriptional cross-talk between SPI-1 and SPI-2. Proc Natl Acad Sci USA 2008; 105(38): 14591-14596
66. Brown NF, Vallance BA, Coombes BK, Valdez Y, Coburn BA, Finlay BB. Salmonella pathogenicity island 2 is expressed prior to penetrating the intestine. PLoS Pathog 2005; 1(3): e32.
67. Husseiny MI, Wartha F, Hensel M. Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2. Vaccine 2007; 25(1): 185-193
68. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998; 281(5376): 565-568 (Pubitemid 28357372)
69. Russmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 2001; 167(1): 357-365
70. Russmann H. Bacterial type III translocation: a unique mechanism for cytosolic display of heterologous antigens by attenuated Salmonella. Int J Med Microbiol 2003; 293(1): 107-112 (Pubitemid 36534602)
71. Panthel K, Meinel KM, Domenech VE, et al. Salmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells. Infect Immun 2005; 73(1): 334-341
72. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282(5396): 2085-2088
73. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000; 97(5): 2163-2167
74. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408(6813): 740-745
75. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167(4): 1882-1885
76. Aliprantis AO, Yang RB, Mark MR, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999; 285(5428): 736-739
77. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673): 245-252
78. Goni F, Prelli F, Schreiber F, et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 2008; 153(3): 679-686
79. Li Y, Wang S, Scarpellini G, et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci USA 2009; 106(2): 593-598
80. Lucas B, Bumann D, Walduck A, et al. Adoptive transfer of CD4+ T cells specific for subunit A of Helicobacter pylori urease reduces H. pylori stomach colonization in mice in the absence of interleu-kin-4 (IL-4)/IL-13 receptor signaling. Infect Immun 2001; 69(3): 1714-1721
81. Karpenko LI, Nekrasova NA, Ilyichev AA, et al. Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine 2004; 22(13-14): 1692-1699
82. Tartz S, Russmann H, Kamanova J, et al. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 2008; 26(47): 5935-5943
83. Ochoa-Reparaz J, Rynda A, Ascon MA, et al. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol 2008;181(2): 954-968
84. Ochoa-Reparaz J, Riccardi C, Rynda A, Jun S, Callis G, Pascual DW. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol 2007; 178(3): 1791-1799
85. Kochetkova I, Trunkle T, Callis G, Pascual DW. Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells. J Immunol 2008; 181(4):2741-2752
86. Wu S, Pascual DW, VanCott JL, et al. Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR. Infect Immun 1995; 63(12): 4933-4938
87. Pascual DW, Hone DM, Hall S, et al. Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun 1999; 67(12): 6249-6256
88. Jun S, Gilmore W, Callis G, Rynda A, Haddad A, Pascual DW. A live diarrheal vaccine imprints a Th2 cell bias and acts as an antiinflammatory vaccine. J Immunol 2005; 75(10): 6733-6740
89. Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005; 133(2): 413-421
90. Boutajangout A, Goni F, Knudsen E, et al. Diminished Amyloidbeta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis 2009; [Epub ahead of print].
91. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27(9): 2050-2057
92. Hauer AD, Habets KL, van Wanrooij EJ, et al. Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 2009; 204(2): 365-371
93. Buckley AM, Wang J, Hudson DL, et al. Evaluation of liveattenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine 2010; 28(4): 1094-1105
94. Fagan PK, Djordjevic SP, Chin J, Eamens GJ, Walker MJ. Oral immunization of mice with attenuated Salmonella typhimurium aroA expressing a recombinant Mycoplasma hyopneumoniae antigen (NrdF). Infect Immun 1997; 65(6): 2502-2507
95. Valentine PJ, Devore BP, Heffron F. Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant. Infect Immun 1998; 66(7): 3378-3383
96. Chen AY, Fry SR, Forbes-Faulkner J, Daggard GE, Mukkur TK. Comparative immunogenicity of M. hyopneumoniae NrdF encoded in different expression systems delivered orally via attenuated S. typhimurium aroA in mice. Vet Microbiol 2006; 114(3-4): 252-259
97. Kong Q, Liu Q, Roland KL, Curtiss R, 3rd. Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect Immun 2009; 77(12):5572-5582
98. Curtiss R, 3rd, Wanda SY, Gunn BM, et al. Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 2009; 77(3): 1071-1082
99. Kong W, Wanda SY, Zhang X, et al. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc Natl Acad Sci USA 2008; 105(27): 9361-9366
100. Chinchilla M, Pasetti MF, Medina-Moreno S, et al. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun 2007; 75(8): 3769-3779
101. Orr N, Galen JE, Levine MM. Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA. Vaccine 2001; 19(13-14): 1694-1700
102. Pickett TE, Pasetti MF, Galen JE, Sztein MB, Levine MM. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun 2000; 68(1): 205-213
103. Dunstan SJ, Simmons CP, Strugnell RA. Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium. Infect Immun 1999; 67(10): 5133-5141
104. Chen AY, Fry SR, Forbes-Faulkner J, Daggard G, Mukkur TK. Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice. J Med Microbiol 2006; 55(Pt 7): 923-929
105. Gahan ME, Webster DE, Wesselingh SL, Strugnell RA, Yang J. Bacterial antigen expression is an important component in inducing an immune response to orally administered Salmonella-delivered DNA vaccines. PLoS One 2009; 4(6): e6062.
106. Loessner H, Endmann A, Leschner S, et al. Improving live attenuated bacterial carriers for vaccination and therapy. Int J Med Microbiol 2008; 298(1-2): 21-26
107. Bauer H, Darji A, Chakraborty T, Weiss S. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther 2005; 12(4): 364-372
108. Gahan ME, Webster DE, Wesselingh SL, Strugnell RA. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium. Vaccine 2007; 25(8): 1476-1483
109. Galen JE, Wang JY, Chinchilla M, et al. A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun 2010; 78(1): 337-347
110. Gentschev I, Glaser I, Goebel W, McKeever DJ, Musoke A, Heussler VT. Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle. Infect Immun 1998;66(5): 2060-2064
111. Chabalgoity JA, Villareal-Ramos B, Khan CM, Chatfield SN, de Hormaeche RD, Hormaeche CE. Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-guest antigen fusions in a Salmonella vaccine carrier. Infect Immun 1995; 63(7): 2564-2569
112. Galan JE, Nakayama K, Curtiss R, 3rd. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 1990; 94(1): 29-35.
113. Kotton CN, Lankowski AJ, Scott N, et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 2006; 24(37-39): 6216-6224
114. Kulkarni RR, Parreira VR, Sharif S, Prescott JF. Oral immunization of broiler chickens against necrotic enteritis with an attenuated Salmonella vaccine vector expressing Clostridium perfringens antigens. Vaccine 2008; 26(33): 4194-4203
115. Galen JE, Nair J, Wang JY, et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 1999; 67(12): 6424-6433
116. Husseiny MI, Hensel M. Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins. Vaccine 2009; 27(28): 3780-3787
117. Garmory HS, Titball RW, Griffin KF, Hahn U, Bohm R, Beyer W. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect Immun 2003; 71(7): 3831-3836
118. Luo F, Feng Y, Liu M, et al. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndromeassociated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol 2007; 14(8): 990-997
119. Hall LJ, Clare S, Pickard D, et al. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine 2009; 27(49): 6894-6904
120. Coulson NM, Fulop M, Titball RW. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 1994; 12(15):1395-1401
121. Haddad D, Liljeqvist S, Kumar S, et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol 1995; 12(3-4): 175-186
122. Newton SM, Jacob CO, Stocker BA. Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science 1989; 244(4900): 70-72
123. Newton SM, Kotb M, Poirier TP, Stocker BA, Beachey EH. Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellin. Infect Immun 1991; 59(6): 2158-2165
124. Hess J, Gentschev I, Miko D, et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996; 93(4): 1458-1463
125. Gomez-Duarte OG, Pasetti MF, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect Immun 2001; 69(2): 1192-1198
126. Osorio M, Wu Y, Singh S, et al. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect Immun 2009; 77(4):1475-1482
127. Galen JE, Zhao L, Chinchilla M, et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 2004; 72(12): 7096-7106
128. Stokes MG, Titball RW, Neeson BN, et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007; 75(4): 1827-1834
129. Ruiz-Perez F, Leon-Kempis R, Santiago-Machuca A, et al. Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect Immun 2002; 70(7): 3611-3620
130. Luria-Perez R, Cedillo-Barron L, Santos-Argumedo L, OrtizNavarrete VF, Ocana-Mondragon A, Gonzalez-Bonilla CR. A fusogenic peptide expressed on the surface of Salmonella enterica elicits CTL responses to a dengue virus epitope. Vaccine 2007;25(27): 5071-5085
131. Igwe EI, Geginat G, Russmann H. Concomitant cytosolic delivery of two immunodominant listerial antigens by Salmonella enterica serovar typhimurium confers superior protection against murine listeriosis. Infect Immun 2002; 70(12): 7114-7119
132. Konjufca V, Wanda SY, Jenkins MC, Curtiss R, 3rd. A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge. Infect Immun 2006; 74(12): 6785-6796
133. Konjufca V, Jenkins M, Wang S, Juarez-Rodriguez MD, Curtiss R, 3rd. Immunogenicity of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine strains carrying a gene that encodes Eimeria tenella antigen SO7. Infect Immun 2008; 76(12):5745-5753
134. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999; 67(5): 2145-2152
135. Chabalgoity JA, Harrison JA, Esteves A, et al. Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains. Infect Immun 1997; 65(6): 2402-2412
136. Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine 2004; 22(11-12): 1379-1389
137. Petavy AF, Hormaeche C, Lahmar S, et al. An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis 2008; 2(1): e125.
138. Chabalgoity JA, Khan CM, Nash AA, Hormaeche CE. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 1996; 19(4): 791-801.
139. Xu C, Li ZS, Du YQ, et al. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J Gastroenterol 2007; 13(6): 939-944
140. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL. Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine 2001; 19(28-29): 3947-3956
141. Gahan ME, Webster DE, Wijburg OL, Wesselingh SL, Strugnell RA. Impact of prior immunological exposure on vaccine delivery by Salmonella enterica serovar Typhimurium. Vaccine 2008;26(49): 6212-6220
142. Vindurampulle CJ, Attridge SR. Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines. Infect Immun 2003; 71(1): 287-297
143. Abdul-Wahid A, Faubert G. Mucosal delivery of a transmissionblocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine 2007; 25(50): 8372-8383
144. Pasetti MF, Barry EM, Losonsky G, et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 2003; 77(9): 5209-5217
145. Sevil Domenech VE, Panthel K, Winter SE, Russmann H. Het-erologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction. Vaccine 2008; 26(15): 1879-1886
146. Berchtold C, Panthel K, Jellbauer S, et al. Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhi-murium. Infect Immun 2009; 77(12): 5501-5508
147. Arnold H, Bumann D, Felies M, et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect Immun 2004; 72(11): 6546-6553
148. Zekarias B, Mo H, Curtiss R, 3rd. Recombinant attenuated Salmonella enterica serovar typhimurium expressing the carboxy-terminal domain of alpha toxin from Clostridium perfringens induces protective responses against necrotic enteritis in chickens. Clin Vaccine Immunol 2008; 15(5): 805-816
149. Galen JE, Chinchilla M, Pasetti MF, et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2009; 199(3): 326-335
150. Bumann D, Behre C, Behre K, et al. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine Jan 8;28(3): 707-713
151. Curtiss R, 3rd, Hassan JO. Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Vet Immunol Immunopathol 1996; 54(1-4): 365-372
152. Holt PS, Gast RK, Kelly-Aehle S. Use of a live attenuated Salmonella typhimurium vaccine to protect hens against Salmonella enteritidis infection while undergoing molt. Avian Dis 2003; 47(3):656-661
153. Babu U, Scott M, Myers MJ, et al. Effects of live attenuated and killed Salmonella vaccine on T-lymphocyte mediated immunity in laying hens. Vet Immunol Immunopathol 2003; 91(1): 39-44.
154. Betancor L, Schelotto F, Fernandez M, Pereira M, Rial A, Chabalgoity JA. An attenuated Salmonella Enteritidis strain derivative of the main genotype circulating in Uruguay is an effective vaccine for chickens. Vet Microbiol 2005; 107(1-2): 81-89
155. Pan Z, Zhang X, Geng S, et al. Priming with a DNA vaccine delivered by attenuated Salmonella typhimurium and boosting with a killed vaccine confers protection of chickens against infection with the H9 subtype of avian influenza virus. Vaccine 2009; 27(7):1018-1023
156. Li L, Fang W, Li J, Huang Y, Yu L. Oral DNA vaccination with the polyprotein gene of infectious bursal disease virus (IBDV) delivered by the attenuated Salmonella elicits protective immune responses in chickens. Vaccine 2006; 24(33-34): 5919-5927
157. Heussler VT, Taracha EL, Musoke A, Duchateau L, McKeever DJ. Immunisation with live attenuated Salmonella dublin expressing a sporozoite protein confers partial protection against Theileria parva. Vaccine 1998; 16(8): 834-841
158. Fagan PK, Walker MJ, Chin J, Eamens GJ, Djordjevic SP. Oral immunization of swine with attenuated Salmonella typhimurium aroA SL3261 expressing a recombinant antigen of Mycoplasma hyopneumoniae (NrdF) primes the immune system for a NrdF specific secretory IgA response in the lungs. Microb Pathog 2001;30(2): 101-110
159. Chabalgoity JA, Moreno M, Carol H, Dougan G, Hormaeche CE. Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine 2000; 19(4-5): 460-469
160. Forrest BD, LaBrooy JT, Attridge SR, et al. Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans. J Infect Dis 1989; 159(1): 145-146
161. Tacket CO, Forrest B, Morona R, et al. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun 1990; 58(6): 1620-1627
162. Gonzalez CR, Noriega FR, Huerta S, et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998; 16(9-10): 1043-1052
163. Tacket CO, Kelly SM, Schodel F, et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 1997; 65(8):3381-3385 (Pubitemid 27342425)
164. Tacket CO, Galen J, Sztein MB, et al. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 2000; 97(2): 146-153
165. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQdeleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000;68(4): 2135-2141
166. Bumann D, Metzger WG, Mansouri E, et al. Safety and immuno-genicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001; 20(5-6): 845-852
167. Metzger WG, Mansouri E, Kronawitter M, et al. Impact of vectorpriming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004;22(17-18): 2273-2277
168. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol 2004; 22(1): 3-4.
169. Senzer N, Nemunaitis J. A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 2009; 11(1): 54-61.
170. Penuelas I, Boan J, Marti-Climent JM, et al. Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. Mol Imaging Biol 2004; 6(4): 225-238
171. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005;12(1): 153-163
172. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291-334.
173. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006; 208(2): 290-298
174. Jia LJ, Hua ZC. Development of bacterial vectors for tumortargeted gene therapy. Methods Mol Biol 2009; 542: 131-154
175. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991; (262): 3-11.
176. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22(3): 313-320
177. Weiss S, Chakraborty T. Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr Opin Biotechnol 2001; 12(5): 467-472 (Pubitemid 32972171)
178. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66(2):165-170 (Pubitemid 32521423)
179. Agorio C, Schreiber F, Sheppard M, et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9(5): 416-423
180. Forbes NS, Munn LL, Fukumura D, Jain RK. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 2003; 63(17): 5188-5193
181. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006; 28(1): 84-94.
182. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20(1): 142-152
183. Nemunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003; 10(10): 737-744
184. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005; 65(9): 3920-3927
185. Chen G, Wei DP, Jia LJ, et al. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci 2009; 100(12): 2437-2443
186. Kimura H, Zhang L, Zhao M, et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif 2010; 43(1): 41-48
187. Hoffman RM. Tumor-targeting amino acid auxotrophic Salmonella typhimurium. Amino Acids 2009; 37(3): 509-521
188. Hayashi K, Zhao M, Yamauchi K, et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 2009; 8(6): 870-875
189. Hayashi K, Zhao M, Yamauchi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 2009; 106(6): 992-998
190. Nagakura C, Hayashi K, Zhao M, et al. Efficacy of a geneticallymodified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 2009; 29(6): 1873-1878
191. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104(24): 10170-10174
192. Zhao M, Yang M, Ma H, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66(15): 7647-7652
193. Lee CH, Wu CL, Shiau AL. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 2008; 122(4): 930-935
194. Ganai S, Arenas RB, Forbes NS. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 2009; 101(10): 1683-1691
195. Fu W, Chu L, Han X, Liu X, Ren D. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dualapoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models. J Gene Med 2008; 10(6): 690-701.
196. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Inhibition of tumor growth using salmonella expressing Fas ligand. J Natl Cancer Inst 2008; 100(15): 1113-1116
197. Friedlos F, Lehouritis P, Ogilvie L, et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res 2008; 14(13): 4259-4266
198. King I, Itterson M, Bermudes D. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. Methods Mol Biol 2009; 542: 649-659
199. al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G, Chouaib S. Potent anti-tumor activity of systemicallyadministered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol 2009;130(1): 89-97.
200. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104(31): 12879-12883
201. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. IL-18producing Salmonella inhibit tumor growth. Cancer Gene Ther 2008; 15(12): 787-794
202. Fernandez-Cabezudo MJ, Mechkarska M, Azimullah S, al-Ramadi BK. Modulation of macrophage proinflammatory functions by cytokine-expressing Salmonella vectors. Clin Immunol 2009; 130(1):51-60.
203. Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. J Pediatr Surg 2008; 43(6): 1153-1158
204. Meng FP, Ding J, Yu ZC, et al. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J Gastroenterol 2005; 11(12): 1833-1836
205. Gentschev I, Fensterle J, Schmidt A, et al. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. BMC Cancer 2005; 5: 15.
206. Bereta M, Hayhurst A, Gajda M, et al. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine 2007; 25(21): 4183-4192
207. Jia LJ, Xu HM, Ma DY, et al. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther 2005; 4(8): 840-845
208. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005; 12(2): 175-184
209. Yang N, Zhu X, Chen L, Li S, Ren D. Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol Ther 2008; 7(1): 145-151
210. Zhang L, Gao L, Zhao L, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007; 67(12): 5859-5864
211. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57(20): 4537-4544
212. Soghomonyan SA, Doubrovin M, Pike J, et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther 2005; 12(1): 101-108
213. Sznol M, Lin SL, Bermudes D, Zheng LM, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 2000; 105(8): 1027-1030
214. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhi-murium. Proc Natl Acad Sci USA 2005; 102(3): 755-760 (Pubitemid 40282738)